Inhibitors of the farnesoid X receptor and uses in medicine

1. A method of treating a disease or disorder selected from obesity, type 2 diabetes, insulin resistance, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and alcoholic liver disease in a mammal in need thereof, comprising administering to the mammal an effective amount of a compound of formula (I):

wherein R 1 and R 2 are independently selected from hydrogen, alkyl, and C(═O)R 3 ,

R 4 is selected from hydrogen, alkyl, and C(═O)R 3 ,

X is selected from C═O and CH 2 ,

Y is selected from CH 2 , NR 5 , O, S, SO, SO 2 , and Se,

or X and Y taken together form C═C,

Z is selected from COOR 6 , SO 3 R 7 , P(═O)(OR 8 ) 2 and NR 9 R 10 ,

R 3 , R 5 , R 6 , R 7 , R 8 R 9 , and R 10 are independently selected from hydrogen, alkyl, and aryl,

in is an integer of 1 to 6, and

n is an integer of 1 to 6,

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound has formula (I), X is C═O, m is 1, Y is NH, and n is an integer of 1 to 6.

3. The method of claim 2 , wherein the compound is selected from:

4. The method of claim 2 , wherein the compound is selected from:

5. The method of claim 1 , wherein X is CH 2 , Y is selected from NH, O, S, and Se, m is 1, n is 2, and Z is SO 3 H.

6. The method of claim 5 , wherein the compound is selected from:

7. The method of claim 1 , wherein the compound is selected from:

8. The method of claim 1 , wherein the disease or disorder is selected from type 2 diabetes, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

9. The method of claim 1 , wherein the compound or salt thereof is administered orally.